Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Bibliographic Data
In this cohort study of US patients with T2D, GLP-1 RA use increased, but remained low overall for treatment of T2D, particularly among patients with ASCVD who are likely to derive the most benefit. Asian, Black, and Hispanic patients and those with low income were less likely to receive treatment with a GLP-1 RA. Strategies to lower barriers to GLP-1 RA use, such as lower cost, are needed to prevent the widening of well-documented inequities in cardiovascular disease outcomes in the US
Diabetes mellitus · Environmental health · Ethnic group · Population · Retrospective cohort study · Socioeconomic status · Type 2 diabetes · Demography · Diabetes Treatment and Management · Gastroesophageal reflux and treatments · Heart Failure Treatment and Management · Medicine · Endocrinology · Gerontology · Internal Medicine
“Yeah but …”
Racial and Ethnic Differences in Diabetes Treatment Modality Selection
Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes
Enhanced Participation in Diabetes Screening and Care After Gestational Diabetes Through Community Health Workers
Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups
Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State
Competing Cultural Discourses of GLP-1 Agonists
Saying no to weight-loss drugs
Thin & waif-like
Impact of Race and Ethnicity on Severe Hypoglycemia Associated with Sulfonylurea Use for Type 2 Diabetes among Veterans
| Citations per year | 3.33 |
|---|---|
| Citation span | 2023 - 2026 (4) |
| Highly cited | No |